2023 / 01

Next Paper
DOI: 10.47183/mes.2023.003

ORIGINAL RESEARCH

Clinical and virological characteristics of chronic hepatitis B and response to antiviral therapy

Nguyen Thi-Hanh1, Melnikova LI2, Ilchenko LYu1,3, Kyuregyan KK4, Gordeychuk IV3, Bondarenko NL2
About authors

1 Pirogov Russian National Research Medical University, Moscow, Russia

2 Clinical Hospital № 85 of Federal Medical-Biological Agency, Moscow, Russia

3 Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products, Moscow, Russia

4 Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia

Correspondence should be addressed: Nguyen Thi-Hanh
Akademika Volgina, 39, Moscow, 117437, Russia; ur.liam@hnahrd

About paper

Author contribution: Nguyen Thi-Hanh — sample collection, data analysis, manuscript writing; Melnikova LI — sample collection, data analysis; Ilchenko LYu — study design, data analysis, manuscript editing; Kyuregyan KK — literature review; Gordeychuk IV — data analysis; Bondarenko NL — editing and approval of the final version of the article.

Compliance with ethical standards: the study was approved by the Ethics Committee of Pirogov Russian National Research Medical University (protocol № 213 of 13 December 2021).

Received: 2022-12-08 Accepted: 2023-02-17 Published online: 2023-03-05
|
Table 1. Comparative characteristics of HBeAg(+) and HBeAg(–) patients
Note: the data are presented as МЕ [25th and 75th percentiles] or n/N (%); *p — significance level.
Table 2. Antiviral drugs used for treatment of CHB (n = 66)
Note: ETV — entecavir; TBV — telbivudine; TDF — tenofovir disoproxil fumarate; LAM — lamivudine; PEG-IFN-α-2a — pegylated interferon α-2а; * — AVT in 2009–2011; * * — TBV for 12 months in 2009–2010, then ETV.
Table 3. Comparative characteristics of HBeAg(+) and HBeAg(–) patients who received NAs
Note: the data are presented as МЕ [25th and 75th percentiles] or n/N (%); *p — significance level.
Table 4. Comparative efficiency of antiviral therapy with NAs
Note: the data are presented as n/N (%).
Table 5. Comparative efficiency of antiviral therapy with NAs in the HBeAg(+) and HBeAg(–) patients
Note: the data are presented as n/N (%); *p — significance level.
Table 6. Univariate and multivariate analysis of the raw factors associated with VR after 48 weeks of therapy with the nucleos(t)ide analogues
Note: *p — significance level.